{"nctId":"NCT03926130","briefTitle":"A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","startDateStruct":{"date":"2019-07-23","type":"ACTUAL"},"conditions":["Crohn's Disease"],"count":1158,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"300 mg Mirikizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Mirikizumab"]},{"label":"90 mg Ustekinumab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ustekinumab"]},{"label":"300 mg Mirikizumab (Adolescents)","type":"EXPERIMENTAL","interventionNames":["Drug: Mirikizumab"]}],"interventions":[{"name":"Mirikizumab","otherNames":["LY3074828"]},{"name":"Mirikizumab","otherNames":["LY3074828"]},{"name":"Ustekinumab","otherNames":[]},{"name":"Ustekinumab","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of CD for at least 3 months prior to baseline\n* Confirmed diagnosis of moderate to severe CD as assessed by SF, AP score, and SES-CD\n* Demonstrated intolerance, loss of response or inadequate response to conventional or to biologic therapy for CD\n* If female, subject must meet the contraception recommendations\n\nExclusion Criteria:\n\n* Have a current diagnosis of ulcerative colitis, inflammatory bowel disease-unclassified (IBD-U) (formerly known as indeterminate colitis) or short bowel syndrome\n* Currently have or are suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained, adequately treated and resolved at least 3 weeks prior to baseline or 8 weeks prior to baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery\n* Have a stoma, ileoanal pouch or ostomy\n* Have had a bowel resection within 6 months, or any kind of intra-abdominal or extra abdominal surgery within 3 months of baseline\n* Have ever received any monoclonal antibodies binding IL-23","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","maximumAge":"80 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab)","description":"Clinical response by patient reported outcome (PRO) defined as ≥30% decrease in stool frequency (SF) and/or abdominal pain (AP) \\& neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).\n\nEndoscopic response defined as ≥50% reduction from baseline in total Simple Endoscopic Score for Crohn's Disease (SES-CD) score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \\& size of ulcers (none=0; diameter 0.1-0.5 cm=1; 0.5-2 cm=2; \\>2 cm=3); extent of ulcerated surface (none=0; \\<10%=1; 10% to 30%=2; \\>30%=3); extent of affected surface (none=0; \\<50%=1; 50% to 75%=2; \\>75%=3); presence \\& type of narrowing (none=0; single, can be passed=1; multiple, can be passed=2; cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null},{"groupId":"OG001","value":"38.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission at Week 52 (Placebo and Mirikizumab)","description":"Clinical response by PRO defined as ≥ 30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).\n\nClinical remission defined as Crohn's Disease Activity Index (CDAI) total score \\<150. The CDAI is an 8-item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \\[hematocrit\\]).. Total score range of 0 to 600 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":null},{"groupId":"OG001","value":"45.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Adult Participants Achieving Endoscopic Response at Week 12 (Placebo and Mirikizumab)","description":"Endoscopic Response defined as ≥50% reduction from baseline in SES-CD total score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \\& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \\>2 cm = 3); extent of ulcerated surface (none = 0; \\<10% = 1; 10% to 30% = 2; \\>30% = 3); extent of affected surface (none = 0; \\<50% = 1; 50% to 75% = 2; \\>75% = 3); presence \\& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG001","value":"32.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Adult Participants Achieving Endoscopic Response at Week 52","description":"Endoscopic Response defined as ≥50% reduction from baseline in SES-CD total score. SES-CD evaluates 4 variables assessed in 5 bowel segments, each scored from 0-3: presence \\& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \\>2 cm = 3); extent of ulcerated surface (none = 0; \\<10% = 1; 10% to 30% = 2; \\>30% = 3); extent of affected surface (none = 0; \\<50% = 1; 50% to 75% = 2; \\>75% = 3); presence \\& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"48.4","spread":null},{"groupId":"OG002","value":"46.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Adult Participants Achieving Clinical Remission at Week 12 (Placebo and Mirikizumab)","description":"Clinical remission defined as CDAI total score \\<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \\[hematocrit\\]). Total score range of 0 to 600 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.1","spread":null},{"groupId":"OG001","value":"37.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Adult Participants Achieving Clinical Remission at Week 52","description":"Clinical remission defined as CDAI total score \\<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \\[hematocrit\\]). Total score range of 0 to 600 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":null},{"groupId":"OG001","value":"54.1","spread":null},{"groupId":"OG002","value":"48.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Adult Participants Achieving Endoscopic Remission at Week 12 (Placebo and Mirikizumab)","description":"Endoscopic remission is defined as SES-CD Total Score ≤4 and at least a 2-point reduction from baseline and no subscore \\>1. SES-CD evaluates 4 endoscopic variables in 5 bowel segments and each of the 20 individual variables is scored from 0-3: presence \\& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \\>2 cm = 3); extent of ulcerated surface (none = 0; \\<10% = 1; 10% to 30% = 2; \\>30% = 3); extent of affected surface (none = 0; \\<50% = 1; 50% to 75% = 2; \\>75% = 3); presence \\& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed =3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \\>1 is defined as no segmental subscore (sum of the 4 individual variable scores for each of the 5 bowel segments) \\>1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"10.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Urgency Numeric Rating Scale (NRS) at Week 12 in Adult Participants (Placebo and Mirikizumab)","description":"The Urgency NRS is a single patient-reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.58","spread":"0.168"},{"groupId":"OG001","value":"-2.44","spread":"0.099"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Urgency NRS at Week 52 in Adult Participants (Placebo and Mirikizumab)","description":"The Urgency NRS is a single patient-reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.23","spread":"0.180"},{"groupId":"OG001","value":"-3.24","spread":"0.106"}]}]}]},{"type":"SECONDARY","title":"Percentage of Adult Participants Achieving Clinical Response at Week 12 and Clinical Remission by PRO at Week 52 (Placebo and Mirikizumab)","description":"Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \\& neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).\n\nClinical Remission by PRO defined as SF≤3 and not worse than baseline (as per Bristol Stool Scale Category 6 or 7) and AP ≤1 and no worse than baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":null},{"groupId":"OG001","value":"45.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Remission at Week 52 (Placebo and Mirikizumab)","description":"Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \\& neither score worse than baseline. SF (number of liquid or very soft stools) per Bristol Stool Scale Category 6 or 7 \\& AP (4-point scale:0=none,1=mild,2=moderate,3=severe). Endoscopic remission=SES-CD Total Score ≤4 \\& at least 2-point reduction from baseline \\& no subscore \\>1.SES-CD evaluates 4 endoscopic variables in 5 bowel segments \\& each of 20 individual variables scored 0-3: presence \\& size of ulcers (none=0;diameter 0.1-0.5 cm=1;0.5-2 cm=2;\\>2 cm=3);extent of ulcerated surface (none=0;\\<10%=1;10% to 30%=2;\\>30%=3);extent of affected surface (none=0;\\<50%=1;50% to 75%=2;\\>75%=3);presence \\& type of narrowing (none=0;single,can be passed=1;multiple,can be passed=2;cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56;higher scores indicating more severe disease. No subscore \\>1=no segmental subscore (sum of the 4 individual variable scores for each of the 5 bowel segments) \\>1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"15.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Adult Participants Achieving Clinical Response at Week 12 and Corticosteroid-free Clinical Remission at Week 52 (Placebo and Mirikizumab)","description":"Clinical response by PRO defined as ≥30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).\n\nClinical remission defined as CDAI total score \\<150. The CDAI is an 8- item disease activity measure comprised of a composite of 3 patient-reported items: AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe); SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7; and general well-being (0=generally well, 1=slightly under par, 2=poor, 3=very poor, 4=terrible), and 5 physician-reported/laboratory items (physical signs and a laboratory parameter \\[hematocrit\\]). Total score range of 0 to 600 points.\n\nCorticosteroid-free clinical remission by CDAI is defined as achieving clinical remission by CDAI at Week 52 and being corticosteroid free from Week 40 to Week 52.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"43.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in C-Reactive Protein (CRP) at Week 52 in Adult Participants (Placebo and Mirikizumab)","description":"Change from baseline in CRP","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"0.087"},{"groupId":"OG001","value":"-0.93","spread":"0.051"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fecal Calprotectin at Week 52 in Adult Participants (Placebo and Mirikizumab)","description":"Change from baseline in Fecal Calprotectin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.19","spread":"0.117"},{"groupId":"OG001","value":"-1.41","spread":"0.067"}]}]}]},{"type":"SECONDARY","title":"Percentage of Adult Participants Achieving Clinical Response at Week 12 and Resolution of Baseline Extraintestinal Manifestations (EIMs) at Week 52 (Placebo and Mirikizumab)","description":"Clinical response by PRO defined as ≥30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null},{"groupId":"OG001","value":"43.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Adult Participants Achieving Clinical Response at Week 12 and ≥50% Reduction in Number of Draining Cutaneous Fistulae at Week 52 in Participants With Draining Cutaneous Fistulae at Baseline (Placebo and Mirikizumab)","description":"Clinical response by PRO defined as ≥ 30% decrease in SF and/or AP and neither score worse than baseline. SF (number of liquid or very soft stools) as per Bristol Stool Scale Category 6 or 7 and AP (4-point scale: 0=none, 1=mild, 2=moderate, 3=severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"21.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Health Related Quality of Life at Week 52 in Adult Participants: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Placebo and Mirikizumab)","description":"The IBDQ is a 32-item patient completed questionnaire that measures 4 aspects of patients' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function. Responses are graded on a 7-point Likert scale in which 7 denotes \"not a problem at all\" and 1 denotes \"a very severe problem.\" IBDQ total score is calculated as the sum of all questions. Scores range from 32 to 224; a higher score indicates a better quality of life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":"2.316"},{"groupId":"OG001","value":"43.82","spread":"1.365"}]}]}]},{"type":"SECONDARY","title":"Adult Population Pharmacokinetics (PopPK): Area Under the Concentration Time Curve (AUC) of Mirikizumab","description":"PopPK: AUC of Mirikizumab","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1820","spread":"38.1"},{"groupId":"OG001","value":"220","spread":"55.9"}]}]}]},{"type":"POST_HOC","title":"Percentage of Adult Participants Achieving Alternate Endoscopic Remission at Week 12 (Placebo and Mirikizumab)","description":"Alternate endoscopic remission is defined as SES-CD Total Score ≤4 and at least a 2-point reduction from baseline and no subscore \\>1. SES-CD evaluates 4 endoscopic variables in 5 bowel segments and each of the 20 individual variables is scored from 0-3: presence \\& size of ulcers (none = 0; diameter 0.1-0.5 cm = 1; 0.5-2 cm = 2; \\>2 cm = 3); extent of ulcerated surface (none = 0; \\<10% = 1; 10% to 30% = 2; \\>30% = 3); extent of affected surface (none = 0; \\<50% = 1; 50% to 75% = 2; \\>75% = 3); presence \\& type of narrowing (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed =3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \\>1 is defined as no subscore \\>1 in any of the 20 individual variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]}]},{"type":"POST_HOC","title":"Percentage of Adult Participants Achieving Clinical Response at Week 12 and Alternate Endoscopic Remission at Week 52 (Placebo and Mirikizumab)","description":"Clinical Response by PRO defined as ≥30% decrease in SF and/or AP \\& neither score worse than baseline. SF (number of liquid or very soft stools) per Bristol Stool Scale Category 6 or 7 \\& AP (4-point scale:0=none,1=mild,2=moderate,3=severe).\n\nAlternate endoscopic remission defined as SES-CD Total Score ≤4 \\& at least 2-point reduction from baseline \\& no subscore \\>1.SES-CD evaluates 4 endoscopic variables in 5 bowel segments \\& each of 20 individual variables scored 0-3: presence \\& size of ulcers (none=0;diameter 0.1-0.5 cm=1;0.5-2 cm=2;\\>2 cm=3); extent of ulcerated surface (none=0;\\<10%=1;10% to 30%=2;\\>30%=3);extent of affected surface (none=0;\\<50%=1;50% to 75%=2;\\>75%=3); presence \\& type of narrowing (none=0;single,can be passed=1;multiple,can be passed=2;cannot be passed=3). Total is sum of all scores across all bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \\>1 is defined as no subscore \\>1 in any of the 20 individual variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"23.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":37,"n":211},"commonTop":["Covid-19","Anaemia","Upper respiratory tract infection","Nasopharyngitis","Headache"]}}}